Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;36(11):725-737.
doi: 10.1016/j.it.2015.09.007.

Interferons and the Immunogenic Effects of Cancer Therapy

Andy J Minn  1
Affiliations
Review

Interferons and the Immunogenic Effects of Cancer Therapy

Andy J Minn. Trends Immunol. 2015 Nov.

Abstract

Much of our understanding on resistance mechanisms to conventional cancer therapies such as chemotherapy and radiation has focused on cell intrinsic properties that antagonize the detrimental effects of DNA and other cellular damage. However, it is becoming clear that the immune system and/or innate immune signaling pathways can integrate with these intrinsic mechanisms to profoundly influence treatment efficacy. In this context, recent evidence indicates that interferon (IFN) signaling has an important role in this integration by influencing immune and intrinsic/non-immune determinants of therapy response. However, IFN signaling can be both immunostimulatory and immunosuppressive, and the factors determining these outcomes in different disease settings are unclear. Here I discuss the regulation and molecular events in cancer that are associated with these dichotomous functions.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cancer cell intrinsic and immune determinants of response to chemotherapy and radiation can be regulated by the opposing functions of interferon signaling
DNA damage caused by chemotherapy or radiation initiates either apoptosis or regulated necrosis to release DAMPs. These DAMPs can be well-known immune activators such as HMGB1, ATP, or calreticulin (CRT) that get either secreted extracellularly or exposed on the plasma membrane. These DAMPs activate antigen presenting cells (APCs), with HMGB1 binding to TLR4 shown as an example. Intracellular DAMPs can be nucleic acids that include mitochondrial DNA (mtDNA), single-stranded DNA (ssDNA), ssRNA, or double-stranded RNA (dsRNA). The DNA is sensed by the cytosolic DNA sensor cGAS to activate STING, while the RNA is detected by TLRs and RLRs. Additionally, DNA from the tumor can be transferred to antigen presenting cells (APCs) where it can activate STING as well. STING and TLRs/RLRs increase type one interferon (IFN-I) production. Like HMGB1/TLR4, this enhances APC cross-priming of T cells. Tumor-reactive T cells produce high levels of interferon gamma (IFNg) and lyse cancer cells. Both IFN-I and IFNg have additional anti-tumor effects such as promoting cancer cell death. However, both IFN-I and IFNg can also promote immunosuppression and cancer cell intrinsic resistance to therapy. IFN-I can enhance IL-10 production and upregulate PD-L1 on APCs, making them immune suppressive. IFN-I and IFNg can upregulate PD-L1 on cancer cells in a phenomenon called adaptive resistance that leads to T cell exhaustion. In cancer cells, unphosphorylated STAT1 (U-STAT1) accumulates and sustains the expression of a subset of ISGs that include the Interferon-Related DNA Damage Resistance Signature (IRDS). The IRDS mediates resistance to radiation and chemotherapy, possibly by increasing DNA repair or inhibiting NK and T cell function through unclear ISGs and mechanisms. However, one mechanism involves the activation of RLRs by stromal cell-derived exosomes (tan box). This also increases IRDS and enhances the transcription of NOTCH3 target genes, which expands therapy-resistant tumor-initiating cells (not shown). Blue boxes indicate anti-tumor and immunostimulatory effects. Cyan boxes indicate pro-tumor and immuosuppressive effects.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;365:1687–1717. - PubMed
    1. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;366:2087–2106. - PubMed
    1. Yom SS. Radiation treatment of head and neck cancer. Surg Oncol Clin N Am. 2015;24:423–436. - PubMed
    1. Rusthoven CG, et al. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. Ann Transl Med. 2015;3:149. - PMC - PubMed
    1. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516. - PMC - PubMed